Sarah Walter, PhD came to Antiva from Labrys Biologics where she oversaw Preclinical Development and Scientific Affairs until their acquisition by Teva Pharmaceuticals in 2014. Prior to Labrys, Sarah worked at KAI Pharmaceuticals for 9 years where she was involved in multiple stages of development for their lead program, KAI-4169, until KAI’s acquisition by Amgen in 2012. Sarah received her PhD in Molecular Pharmacology from Stanford University and a BA in chemistry from Swarthmore College.

• 

  Senior Vice President of Nonclinical Development & Global Health Strategy in Antivabio

  Stopping Cancer Before It Starts